Altamira Therapeutics | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
Apr 22 22:18 ET
Altamira Therapeutics | EFFECT: Others
Apr 18 06:06 ET
Altamira Therapeutics | 424B4: Prospectus
Apr 17 16:25 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Apr 16 17:01 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Apr 10 08:32 ET
Altamira Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Apr 10 08:17 ET
Altamira Therapeutics | F-1: Registration statement for securities of certain foreign private issuers
Apr 10 08:17 ET
Altamira Therapeutics | 20-F: Registration statement / Annual report / Transition report
Apr 10 08:02 ET
Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Thomas Meyer(1.2%)
Mar 13 11:08 ET
Altamira Therapeutics | 424B4: Prospectus
Jan 22 00:00 ET
Altamira Therapeutics | EFFECT: Others
Jan 22 00:00 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Jan 19 00:00 ET
Altamira Therapeutics | 424B5: Prospectus
Jan 19 00:00 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Jan 19 00:00 ET
Altamira Therapeutics | CORRESP: CORRESP
Jan 17 11:41 ET
Altamira Therapeutics | UPLOAD: Others
Jan 16 11:41 ET
Altamira Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers
Jan 8 00:00 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Dec 11, 2023 08:01 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Dec 11, 2023 08:00 ET
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Dec 8, 2023 09:00 ET
No Data
No Data